The American Heart Association (AHA), American College of Cardiology (ACC) and the American Society of heart failure (HFSA) on March 17 released a new joint statement calling for continued use of antagonists of the renin-angiotensin-aldosterone system (RAAS) in patients, regardless of theoretical fear that their use may worsen the results if infection COVID-19.

Recently, a similar statement was made by the European Society of Cardiology (ESC), and the European Society of hypertension, the Canadian Society of cardiovascular disease and the International Society for hypertension.

Experts say that people with cardiovascular disease are exposed to much higher risk of serious complications, including death from COVID-19, however, a recent study – the actual data do not support the need for discontinuation of ACE inhibitors or angiotensin receptor blockers (ARBs), and researchers recommend that doctors take into account all the individual needs of each patient before making any changes in appointments ACE inhibitors or ARBs.

The new coronavirus SARS-CoV-2, which causes COVID-19 infects human cells by binding to receptors APF2 and some animal studies have shown that this mechanism increases the expression APF2 heart.

In the Lancet article assumes that patients with diabetes and hypertension increased regulation APF2 of ACE inhibitors and ARBs may increase the risk of severe and fatal COVID -19.

The authors suggested that these drugs may partially contribute to more severe and deadly COVID-19 observed in people with hypertension, diabetes and cardiovascular disease.

This article received wide coverage in the media and social networks in the UK, resulting in patients treated with their doctors, and in some cases stopped medication.

Overall, the researchers recommend that the RAAS antagonists destination for those patients who are currently appointed by the following drugs for indications such as heart failure, hypertension or coronary heart disease.

However, scientists note, if patients with cardiovascular disease diagnosed COVID-19 have made individual decisions on treatment according to the hemodynamic status of each patient and the clinical picture.

 To date, no evidence of harm or good. More research is needed.

There is also a theory that ACE inhibitors and ARBs may paradoxically be useful in koronavirusniy infection.

This is because APF2 converts angiotensin II to angiotensin 1-7 vazodylyatatornyy, thereby potentially providing a hypotensive effect in animal studies has been shown that both types of drugs reduce severe lung damage in some viral pneumonia.

However, there is currently no experimental or clinical data that demonstrate a positive or negative results in the background use of ACE inhibitors, ARBs, or other antagonists RAAS in COVID-19 or in patients with COVID-19 with cardiovascular disease history, treated such drugs.

American Heart Association does not recommend adding or deleting any treatment-related RAAS, other than those based on standard clinical practice.

Literary links are amended Webcardio.org
http://www.webcardio.org/chy-pryznachaty-inghibitory-apf-i-bra-kardiologhichnym–patsijentam-z-covid-19.aspx